Low vs standard dose of recombinant tissue plasminogen activator in treating East Asian patients with acute ischemic stroke

Neurology India

Volumn 59, Issue 2, 2011, Pages 180-184

  Dharmasaroja, Pornpatr A ^a   Pattaraarchachai, Junya ^b  

^a THAMMASAT UNIVERSITY   (Thailand)

^b THAMMASAT UNIVERSITY   (Thailand)

Author keywords

Asia; dose; intravenous thrombolysis; ischemic stroke; Thai

Indexed keywords

ALTEPLASE;

ACUTE ISCHEMIC STROKE; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HUMAN; MEDLINE; MORTALITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN ISCHEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FAR EAST; FIBRINOLYTIC AGENTS; HUMANS; RECOMBINANT PROTEINS; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 79955408297     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.79132     Document Type: Article

References (25)

1. Adams HP Jr, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, et al. Guidelines for the early management of patients with ischemic stroke: A scientific statement from the stroke council of the American Stroke Association. Stroke 2003;34:1056-83. (Pubitemid 36402991)
2. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr; American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: A science advisory from the American Heart Association/ American Stroke Association. Stroke 2009;40:2945-8.
3. Hankey GJ. Thrombolysis for acute ischemic stroke. J Clin Neurosci 2001;8:103-5.
4. Ueshima S, Matsuo O. The differences in thrombolytic effects of administrated recombinant t-PA between Japanese and Caucasians. Thromb Haemost 2002;87:544-6. (Pubitemid 34232504)
5. Toyoda K, Koga M, Naganuma M, Shiokawa Y, Nakagawara J, Furui E, et al. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients; General outcomes and prognostic factors from the SAMURAI register. Stroke 2009;40:3591-5.
6. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006;37:1810-5. (Pubitemid 44297734)
7. Chao AC, Hsu HY, Chung CP, Liu CH, Chen CH, Teng MM, et al. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients; The Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study. Stroke 2010;41:885-90.
8. Dharmasaroja PA, Dharmasaroja P, Muengtaweepongsa S. Outcomes of Thai patients with acute ischemic stroke after intravenous thrombolysis. J Neurol Sci 2011;300:74-7.
9. Sharma VK, Tsivgoulis G, Tan JH, Wong LY, Ong BK, Chan BP, et al. Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore. J Stroke Cerebrovasc Dis 2010;19:424-30.
10. Hacke W, Kaste M, Fiesche C, von Kummer R, Davalos A, Meier D, et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-51. (Pubitemid 28470336)
11. Suwanwela NC, Phanthumchinda K, Likitjaroen Y. Thrombolytic therapy in acute ischemic stroke in Asia: The first prospective evaluation. Clin Neurol Neurosurg 2006;108:549-52. (Pubitemid 44189093)
12. Yoneda Y, Yamamoto S, Hara Y, Ohta K, Matsushita M, Yamamoto D, et al. Post-licensed 1-year experience of systemic thrombolysis with tissue plasminogen activator for ischemic stroke in a Japanese neurounit. Clin Neurol Neurosurg 2007;109:567-70. (Pubitemid 47023024)
13. Walgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITSMOST): An observational study. Lancet 2007;369:275-82. (Pubitemid 46138121)
14. Mori E, Minematsu K, Nakagawara J, Yamaguchi T, Sasaki M, Hirano T, et al. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion. Japan Alteplase Clinical Trial II (J-ACT II). Stroke 2010;41:461-5.
15. Nakawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, et al. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice. The Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010;41:1984-9.
16. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-7.
17. Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992;23:632-40.
18. Haley EC Jr, Levy DE, Brott TG, Sheppard GL, Wong MC, Kongable GL, et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992;23:641-5.
19. Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992;42:976-82.
20. Yamaguchi T, Kikuchi H, Hayakawa H, Japanese thrombolysis study group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: A randomized, double-blind, dosecomparison study of duteplase. In: Yamaguchi T, Mori E, Minematsu K, del Zoppo GJ, editors. Thrombolytic therapy in acute ischemic stroke III. Tokyo: Springer-Verlag; 1995. p. 223-9.
21. Sane DC, Stump DC, Topol EJ, Sigmon KN, Clair WK, Kereiakes DJ, et al. Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increase fibrin(ogen) olysis in blacks. The thrombolysis and angioplasty in myocardial infarction study group. Circulation 1991;83:170-5.
22. Iso H, Folsom AR, Sato S, Wu KK, Shimamoto T, Koike K, et al. Plasma fibrinogen and its correlates in Japanese and US population samples. Arterioscler Thromb 1993;13:783-90. (Pubitemid 23164680)
23. Iso H, Folsom AR, Koike KA, Sato S, Wu KK, Shimamoto T, et al. Antigens of tissue plasminogen activator and plasminogen activator inhibitor 1: Correlates in nonsmoking Japanese and Caucasian Men and Women. Thromb Haemost 1993;70:475-80. (Pubitemid 23254679)
24. Kangsadalampai S, Board PG. The Val34Leu polymorphism in A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 1998;92:2766-70. (Pubitemid 28469090)
25. Murata M. Genetic polymorphisms associated with thrombotic disorders in the Japanese population. Fibrinolysis Proteolysis 2000; 14:155-64. (Pubitemid 30409288)